131 related articles for article (PubMed ID: 7513018)
1. Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy.
Shea TC; Mason JR; Breslin M; Bissent E; Mullen M; Taetle R
J Clin Oncol; 1994 May; 12(5):1012-20. PubMed ID: 7513018
[TBL] [Abstract][Full Text] [Related]
2. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
[TBL] [Abstract][Full Text] [Related]
3. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.
Shea TC; Mason JR; Storniolo AM; Newton B; Breslin M; Mullen M; Ward DM; Miller L; Christian M; Taetle R
J Clin Oncol; 1992 Mar; 10(3):464-73. PubMed ID: 1740685
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
[TBL] [Abstract][Full Text] [Related]
5. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.
Elias AD; Ayash L; Anderson KC; Hunt M; Wheeler C; Schwartz G; Tepler I; Mazanet R; Lynch C; Pap S
Blood; 1992 Jun; 79(11):3036-44. PubMed ID: 1350229
[TBL] [Abstract][Full Text] [Related]
6. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
[TBL] [Abstract][Full Text] [Related]
7. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
[TBL] [Abstract][Full Text] [Related]
8. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
9. High-dose carboplatin chemotherapy with GM-CSF and peripheral blood progenitor cell support: a model for delivering repeated cycles of dose-intensive therapy.
Shea TC; Mason JR; Storniolo AM; Bissent E; Breslin M; Mullen M; Taetle R
Cancer Treat Rev; 1993; 19 Suppl C():11-20. PubMed ID: 8106154
[TBL] [Abstract][Full Text] [Related]
10. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
Schneider JG; Crown JP; Wasserheit C; Kritz A; Wong G; Reich L; Norton L; Moore MA
Bone Marrow Transplant; 1994 Dec; 14(6):877-84. PubMed ID: 7536069
[TBL] [Abstract][Full Text] [Related]
13. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy.
Venturini M; Del Mastro L; Melioli G; Balleari E; Garrone O; Pasquetti W; Bason C; Ghio R; Bruzzi P; Rosso R
Cancer; 1994 Oct; 74(8):2300-6. PubMed ID: 7522948
[TBL] [Abstract][Full Text] [Related]
14. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size.
van der Wall E; Richel DJ; Holtkamp MJ; Slaper-Cortenbach IC; van der Schoot CE; Dalesio O; Nooijen WJ; Schornagel JH; Rodenhuis S
Ann Oncol; 1994 Nov; 5(9):795-802. PubMed ID: 7531486
[TBL] [Abstract][Full Text] [Related]
16. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin.
Brugger W; Bross K; Frisch J; Dern P; Weber B; Mertelsmann R; Kanz L
Blood; 1992 Mar; 79(5):1193-200. PubMed ID: 1371415
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
18. Improvement of hematologic recovery after high-dose intensification using peripheral blood progenitor cells (PBPC) mobilized by chemotherapy and GM-CSF.
Lamy T; Drenou B; Grulois I; Leberre C; Dauriac C; Amiot L; Godard M; Fauchet R; LePrise PY
Ann Hematol; 1994 Dec; 69(6):297-302. PubMed ID: 7993937
[TBL] [Abstract][Full Text] [Related]
19. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
Kritz A; Crown JP; Motzer RJ; Reich LM; Heller G; Moore MP; Hamilton N; Yao TJ; Heelan RT; Schneider JG
Cancer; 1993 Apr; 71(8):2515-21. PubMed ID: 8095854
[TBL] [Abstract][Full Text] [Related]
20. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer.
Ho AD; Glück S; Germond C; Sinoff C; Dietz G; Maruyama M; Corringham RE
Leukemia; 1993 Nov; 7(11):1738-46. PubMed ID: 7901454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
